
Zacks has added Avadel Pharmaceuticals (AVDL), Evolution Petroleum (EPM), and FMC Corporation (FMC) to its #5 (Strong Sell) list, driven by significant downward revisions in their current year earnings estimates. Over the last 60 days, AVDL's earnings estimate was revised down 20.8%, EPM's by 89%, and FMC's by 5.5%, indicating a deteriorating financial outlook for these companies.
Zacks has issued a "Strong Sell" rating for three companies – Avadel Pharmaceuticals (AVDL), Evolution Petroleum (EPM), and FMC Corporation (FMC) – placing them on its Rank #5 list. This downgrade is primarily driven by significant downward revisions to their current year earnings estimates over the past 60 days. This indicates a strongly negative sentiment and bearish tone surrounding these stocks. Evolution Petroleum (EPM), an energy company, experienced the most severe revision, with its consensus earnings estimate slashed by 89%. Avadel Pharmaceuticals (AVDL), a biopharmaceutical firm, saw a 20.8% reduction, while agricultural sciences company FMC Corporation (FMC) faced a 5.5% downward adjustment. These widespread revisions across diverse sectors signal a deteriorating fundamental outlook for these specific entities. The collective strongly negative sentiment, with per-ticker scores ranging from -0.6 to -0.9, coupled with a moderate market impact score of 0.55, suggests that these analyst downgrades are significant. Such substantial revisions often precede or accompany negative price action, reflecting diminished confidence in future profitability and company fundamentals.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly negative
Sentiment Score
-0.80
Ticker Sentiment